RadioEmbolization for the ADvancement of Y90 Glass Microspheres Registry

This study is a non-interventional, observational, prospective and global participant data
registry.

Approximately 1000 participants with liver cancers who are treated with TheraSphere® will be
enrolled.

Data regarding participant and treatment characteristics (TheraSphere® and other anti-cancer
treatments) will be collected within a 12-month period post TheraSphere® administration to:

- Assess treatment effectiveness and safety in a real-life administration setting

- Identify prognostic and predictive factors for liver cancer participants receiving
TheraSphere® treatment

Data for dosimetry determination will be collected on approximately 300 HCC participants to
assess:

- Technetium-99m Macroaggregated albumin (99mTc-MAA) normal tissue and tumor Absorbed Dose
using pre-procedural Single Proton Emission Computed Tomography/ Computed Tomography
(SPECT/CT)

- Yttrium-90 and isotopes (Y90) normal tissue and tumor Absorbed Dose using
post-procedural PET/CT (or equivalent for Asia) scans

Inclusion Criteria:

1. Participant is ≥ 18 years of age

2. Participant has confirmed liver cancer

3. Participant is able to provide informed consent according to local requirements/law

4. Participant has a life expectancy of ≥ 3 months

5. Participant is scheduled to receive TheraSphere® treatment

Exclusion Criteria:

1. Participant who has previously received Y90 microspheres

2. Participant who has consented to participate in a BTG-sponsored clinical study that
includes TheraSphere® treatment